Fw: Test between Glucosamine and medicine Reparagen

[Guest guest]



----- Original Message -----

Skip to main content

1-Nov-2007

home | journals A-Z | subject areas | advanced search | authors | reviewers | libraries | jobs | about | my BioMed Central

BMC Complementary and Alternative MedicineVolume 7

Viewing options:

Abstract

PDF (2.2MB) Associated material:

Readers' comments

Pre-publication historyRelated literature:

Other articles by authors

on Google Scholar

Mehta KGala JBhasale SNaik SModak MThakur HDeo N MJ

on PubMed

Mehta KGala JBhasale SNaik SModak MThakur HDeo N MJ

Related articles/pages

on Google

on Google ScholarTools:

Email to a friend

Order reprints

Post a comment

Sign up for article alerts

Post to:

Citeulike

Connotea

Del.icio.us

Digg

Facebook

Research article Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [iSRCTN25438351]

Komal Mehta , Jayesh Gala , Surendra Bhasale , Sattayasheel Naik , Millind Modak , Harshad Thakur , Nivedita Deo and Mark JS

BMC Complementary and Alternative Medicine 2007, 7:34doi:10.1186/1472-6882-7-34

Published:

31 October 2007

Abstract (provisional)

Background

The efficacy and safety of a dietary supplement derived from South American botanicals was compared to glucosamine sulfate in osteoarthritis subjects in a Mumbai-based multi-center, randomized, double-blind study.

Methods

Subjects (n=95) were screened and randomized to receive glucosamine sulfate (n= 47, 1500 mg/day) or reparagen (n=48, 1800 mg/day), a polyherbal consisting of 300 mg of vincaria (Uncaria guianensis) and 1500 mg of RNI 249 (Lepidium meyenii) administered orally, twice daily. Primary efficacy variable was response rate based on a 20% improvement in WOMAC pain scores. Additional outcomes were WOMAC scores for pain, stiffness and function, visual analog score (VAS) for pain, with assessments at 1, 2, 4, 6 and 8 weeks. Tolerability, investigator and subject global assessments and rescue medication consumption (paracetamol) were measured together with safety assessments including vital signs and laboratory based assays.

Results

Subject randomization was effective: age, gender and disease status distribution was similar in both groups. The response rates (20% reduction in WOMAC pain) were substantial for both glucosamine (89%) and reparagen (94%) and supported by investigator and subject assessments. Using related criteria response rates to reparagen were favorable when compared to glucosamine. Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P<0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45-62% reduction in WOMAC or VAS scores). Tolerability was excellent, no serious adverse events were noted and safety parameters were unchanged. Rescue medication use was significantly lower in the reparagen group (p <0.01) at each assessment period. Serum IGF-1 levels were unaltered by treatments.

Conclusion

Both reparagen and glucosamine sulfate produced substantial improvements in pain, stiffness and function in subjects with osteoarthritis. Response rates were high and the safety profile was excellent, with significantly less rescue medication use with reparagen. Reparagen represents a new natural productive alternative in the management of joint health. Trial registration: Current Controlled Trials ISRCTN25438351.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us

© 1999-2007 BioMed Central Ltd unless otherwise stated

No virus found in this incoming message.Checked by AVG Free Edition. Version: 7.5.503 / Virus Database: 269.15.15/1101 - Release Date: 10/31/2007 10:06 AM